Apontis Pharma AG provided revenue guidance for the year 2023. For the year, the company expects revenues of EUR 42.6 million (previously: EUR 51.7 million). The reasons for the changes in forecast revenues and earnings include uncertainties in the supply of the product.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.91 EUR | -0.78% | +5.15% | +89.05% |
Apr. 05 | Apontis Bags Distribution Deal with Novartis Unit for Two Asthma Medications | MT |
Mar. 28 | Apontis Pharma AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+89.05% | 80.24M | |
+48.53% | 780B | |
+41.25% | 627B | |
-6.37% | 353B | |
+20.93% | 334B | |
+8.21% | 296B | |
+17.34% | 244B | |
-1.06% | 217B | |
+10.88% | 214B | |
+4.40% | 161B |
- Stock Market
- Equities
- APPH Stock
- News Apontis Pharma AG
- Apontis Pharma Ag Provides Revenue Guidance for the Year 2023